We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
STING agonist, SMA-2, inhibits clear cell renal cell carcinoma through improving tumor microenvironment.
- Authors
Wang, Wei; Zhang, Fengqing; Hu, Yan; Liu, Guangming
- Abstract
Clear cell renal cell carcinoma (ccRCC) is the most prevalent and lethal subtype of kidney cancer, patients with ccRCC usually have very poor prognosis and short survival. Therefore, it is urgent to develop more effective therapeutics or medications to suppress ccRCC progression. Here, we demonstrated that STING agonist, MSA-2 significantly inhibits tumor progress and prolongs the survival of ccRCC mice by promoting cytokines secretion. Moreover, MSA-2 triggered the trafficking and infiltration of CD8+ T cells, supported by the generation of a chemokine milieu that promoted recruitment and modulation of the immunosuppressive TME in ccRCC. These findings suggest that MSA-2 potentially serves an effective and preferable adjuvant immunotherapy of ccRCC.
- Subjects
RENAL cell carcinoma; TUMOR microenvironment; RENAL cancer; CHEMOKINE receptors; PROGNOSIS
- Publication
Molecular & Cellular Biochemistry, 2024, Vol 479, Issue 7, p1697
- ISSN
0300-8177
- Publication type
Article
- DOI
10.1007/s11010-024-04970-w